Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood disorder evolution: researchers track hidden transformation

NCT ID NCT07203768

Knowledge-focused Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study examines why some patients with essential thrombocythemia (ET) later develop polycythemia vera (PV), a related blood condition. Researchers will review medical records of 678 adults to identify risk factors for this change and compare outcomes between those who progressed and those diagnosed with PV from the start. The goal is to better understand the disease course and improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 678 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Nested case-control study: the prevalence of at least one of the following proliferative conditions in the control group, a neutrophil/lymphocyte ratio (N/L ratio) above the median, an LDH above the median, being JAK2V617F homozygous and having splenomegaly. Comparative retrospective cohort study: it is known that the incidence of the composite outcome (vascular events, cancers, progression to myelofibrosis, progression to acute myeloid leukemia, death) in PV de novo patients.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- ET patients (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) who are JAK2V617F positive and have progressed to PV (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) by 31/12/2020. The date of PV diagnosis will be defined as the index date and this group of patients will be defined as ET-to-PV cases. Exclusion Criteria: * None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia familial thrombocytosis thrombocytosis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycythemia vera Thrombocythemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 12 Octubre University Hospital

    RECRUITING

    Madrid, Spain

  • A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia

    NOT_YET_RECRUITING

    Alessandria, 15121, Italy

  • AOU Careggi, Divisione di Ematologia

    RECRUITING

    Florence, Italy

  • ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia

    NOT_YET_RECRUITING

    Milan, Italy

  • ASST MONZA Ospedale San Gerardo Clinica Ematologica

    NOT_YET_RECRUITING

    Monza, 20900, Italy

  • ASST Papa Giovanni XXIII, SC Ematologia

    RECRUITING

    Bergamo, Italy

  • ASST-Spedali Civili

    NOT_YET_RECRUITING

    Brescia, 25123, Italy

  • Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo

    NOT_YET_RECRUITING

    Naples, 80131, Italy

  • Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Unità di Ematologia

    NOT_YET_RECRUITING

    Verona, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia

    RECRUITING

    Novara, 28100, Italy

  • Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo

    NOT_YET_RECRUITING

    Pavia, Lombardy, 27100, Italy

  • Divisione Ematologia, Ospedale San Bortolo

    RECRUITING

    Vicenza, Veneto, Italy

  • Fondazione IRCCS Cà Grande - Op. Maggiore Policlinico

    NOT_YET_RECRUITING

    Milan, Italy

  • Fondazione Policlinico Universitario Gemelli

    RECRUITING

    Roma, Italy

  • Guy's and St. Thomas' NHS Foundation Trust

    RECRUITING

    London, United Kingdom

  • Hannover Medical School

    RECRUITING

    Hanover, Germany

  • IDIBAPS, Hospital clinic

    RECRUITING

    Barcelona, Spain

  • Mayo Clinic

    ACTIVE_NOT_RECRUITING

    Rochester, Minnesota, 55905-0001, United States

  • Ospedale San Raffaele

    NOT_YET_RECRUITING

    Milan, Italy

  • Policlinico S. Orsola - Malpighi

    NOT_YET_RECRUITING

    Bologna, Italy

  • Presidio Ospedaliero di Pescara

    NOT_YET_RECRUITING

    Pescara, Italy

  • Umberto I Policlinico

    NOT_YET_RECRUITING

    Roma, Italy

  • University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center

    RECRUITING

    Minden, Germany

  • University Hospital Halle

    NOT_YET_RECRUITING

    Halle, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.